CONTRAFECT Corp
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | −$64.6M | −$47.3M | −$34.2M | −$27.9M | −$31.1M | −$26.6M |
| Net income | −$65.2M | −$20.3M | −$28.2M | −$12.8M | −$37.7M | −$15.5M |
| Total assets | $20.7M | $66.8M | $51.1M | $35.0M | $32.9M | $50.2M |
| Total liabilities | $32.5M | $17.4M | $38.5M | $19.5M | $27.3M | $19.0M |
| Equity | −$11.9M | $49.4M | $12.6M | $15.5M | $5.5M | $31.2M |
| EPS (diluted) | $-124.97 | $-44.12 | $-98.95 | — | — | — |
| Shares out. | 39.3M | 39.3M | 15.3M | 79.4M | 73.7M | 41.7M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2022- Operating margin
- —
- Net margin
- —
- Return on equity
- 549.7%
- Return on assets
- −315.1%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 157.3%
- Debt / equity
- —
- Book value / share
- $-0.30
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2022- Altman Z″ (distress)
- -73.72distress
- Accruals / assets
- −92.7%clean
- Piotroski F-Score
- 1/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 severe● 2 warning● 2 good- Negative shareholder equity
- Altman Z″ in the distress zone
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Armistice Capital, LlcPassive (13G)Aug 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Material events
SEC Form 8-K · most recent- Bankruptcy or receivership · Director / officer changeDec 5, 2023
- Costs from exit or disposal · Director / officer changeNov 15, 2023
- Delisting / listing-standard noticeNov 8, 2023
- Delisting / listing-standard noticeSep 29, 2023
- Delisting / listing-standard noticeAug 18, 2023
- Results of operationsAug 14, 2023
- Other material eventJul 25, 2023
- Entered a material agreement · Unregistered equity saleJun 27, 2023
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.